Dr. Bowen noted that his data are about 10 years old now. He holds a soon-to-expire patent on the use of leuprolide for Alzheimer’s and was pursuing that with a corporation. However, the company fell apart and he said he has become free to share the information only now.
But the data are enough for him to be using the treatment on at least a few patients. “I have about five or six people, both men and women, who are taking it in combination with an AChEI. The families are very happy with what they see, and I’m hoping we can get the word out so we can accumulate more data on it.”
On Twitter @alz_gal